Prevalence and Characteristics of Sleep Apnea in Intensive Care Unit Survivors After SARS-CoV-2 Pneumonia.
SARS-CoV-2
intensive care unit
obstructive sleep apnea syndrome
pneumonia
Journal
Nature and science of sleep
ISSN: 1179-1608
Titre abrégé: Nat Sci Sleep
Pays: New Zealand
ID NLM: 101537767
Informations de publication
Date de publication:
2022
2022
Historique:
received:
14
06
2022
accepted:
14
11
2022
entrez:
29
12
2022
pubmed:
30
12
2022
medline:
30
12
2022
Statut:
epublish
Résumé
Sleep apnea (SA) was reported as possibly exacerbating symptoms of COVID-19, a disease induced by SARS-CoV-2 virus. The same comorbidities are common with both pathologies. This study aimed to estimate the prevalence, characteristics of SA and variation in AHI three months after severe COVID-19 requiring intensive care unit (ICU) admission. A prospective cohort of patients admitted to ICU for severe COVID-19 underwent an overnight home polygraphy 3 months after onset of symptoms, as part of a comprehensive follow-up program (pulmonary function tests, 6-minute walk tests and chest CT-scan). Patients with an apnea hypopnea index (AHI) ≥5 were considered as having SA. We performed a comparative descriptive analysis of 2 subgroups according to the existence, severity of SA and indication for effective SA treatment: patients with absent or mild SA (AHI <15) vs patients with moderate to severe SA (AHI ≥15). Among 68 patients included, 62 (91%) had known comorbidities (34 hypertension, 21 obesity, 20 dyslipidemia, 16 type 2 diabetes). It has been observed a preexisting SA for 13 patients (19.1%). At 3 months, 62 patients (91%) had SA with 85.5% of obstructive events. Twenty-four patients had no or a mild SA (AHI <15) and 44 had moderate to severe SA (AHI ≥15). Ischemic heart disease exclusively affected the moderate to severe SA group. Except for thoracic CT-scan which revealed less honeycomb lesions, COVID-19 symptoms were more severe in the group with moderate to severe SA, requiring a longer curarization, more prone position sessions and more frequent tracheotomy. SA involved 91% of patients in our population at 3 months of severe COVID-19 and was mainly obstructive type. Although SA might be a risk factor as well as consequences of ICU care in severe COVID-19 infection, our results underline the importance of sleep explorations after an ICU stay for this disease.
Sections du résumé
Background
UNASSIGNED
Sleep apnea (SA) was reported as possibly exacerbating symptoms of COVID-19, a disease induced by SARS-CoV-2 virus. The same comorbidities are common with both pathologies. This study aimed to estimate the prevalence, characteristics of SA and variation in AHI three months after severe COVID-19 requiring intensive care unit (ICU) admission.
Methods
UNASSIGNED
A prospective cohort of patients admitted to ICU for severe COVID-19 underwent an overnight home polygraphy 3 months after onset of symptoms, as part of a comprehensive follow-up program (pulmonary function tests, 6-minute walk tests and chest CT-scan). Patients with an apnea hypopnea index (AHI) ≥5 were considered as having SA. We performed a comparative descriptive analysis of 2 subgroups according to the existence, severity of SA and indication for effective SA treatment: patients with absent or mild SA (AHI <15) vs patients with moderate to severe SA (AHI ≥15).
Results
UNASSIGNED
Among 68 patients included, 62 (91%) had known comorbidities (34 hypertension, 21 obesity, 20 dyslipidemia, 16 type 2 diabetes). It has been observed a preexisting SA for 13 patients (19.1%). At 3 months, 62 patients (91%) had SA with 85.5% of obstructive events. Twenty-four patients had no or a mild SA (AHI <15) and 44 had moderate to severe SA (AHI ≥15). Ischemic heart disease exclusively affected the moderate to severe SA group. Except for thoracic CT-scan which revealed less honeycomb lesions, COVID-19 symptoms were more severe in the group with moderate to severe SA, requiring a longer curarization, more prone position sessions and more frequent tracheotomy.
Conclusion
UNASSIGNED
SA involved 91% of patients in our population at 3 months of severe COVID-19 and was mainly obstructive type. Although SA might be a risk factor as well as consequences of ICU care in severe COVID-19 infection, our results underline the importance of sleep explorations after an ICU stay for this disease.
Identifiants
pubmed: 36578669
doi: 10.2147/NSS.S377946
pii: 377946
pmc: PMC9791936
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2213-2225Informations de copyright
© 2022 Traore et al.
Déclaration de conflit d'intérêts
Professor Gilles Capellier is the President of Association le Don du Souffle which has developed apnea syndrome diagnostic activities. Professor Virginie Westeel reports grants from SOS Oxygène, during the conduct of the study. The authors report no other conflicts of interest in this work.
Références
Sleep Breath. 2021 Jun;25(2):1155-1157
pubmed: 32989673
J Sleep Res. 1992 Dec;1(4):240-244
pubmed: 10607057
Int Arch Otorhinolaryngol. 2016 Apr;20(2):145-50
pubmed: 27096019
Lancet Respir Med. 2020 Aug;8(8):807-815
pubmed: 32422178
Am J Respir Crit Care Med. 2000 Feb;161(2 Pt 1):369-74
pubmed: 10673173
Obesity (Silver Spring). 2008 Jan;16(1):113-8
pubmed: 18223622
Eur Respir J. 2005 Aug;26(2):319-38
pubmed: 16055882
Eur Respir J. 2017 Jan 3;49(1):
pubmed: 28049168
Chest. 2014 Nov;146(5):1387-1394
pubmed: 25367475
Br J Anaesth. 2020 Aug;125(2):e262-e263
pubmed: 32439072
Signal Transduct Target Ther. 2021 Nov 23;6(1):406
pubmed: 34815399
Am J Physiol Heart Circ Physiol. 2000 Jul;279(1):H234-7
pubmed: 10899061
Am J Respir Crit Care Med. 2005 Jul 1;172(1):114-7
pubmed: 15817803
J Clin Sleep Med. 2017 May 15;13(5):665-666
pubmed: 28416048
Am J Respir Crit Care Med. 1999 Jan;159(1):43-8
pubmed: 9872816
Eur Respir Rev. 2016 Mar;25(139):12-8
pubmed: 26929416
Sleep Breath. 2019 Jun;23(2):463-471
pubmed: 30030695
Sleep Breath. 2021 Mar;25(1):371
pubmed: 32342265
Sleep Med Rev. 2022 Jun;63:101624
pubmed: 35378481
Am J Respir Crit Care Med. 2005 Apr 15;171(8):912-30
pubmed: 15817806
Sleep Med. 2022 Mar;91:226-230
pubmed: 34246548
JAMA. 2020 Apr 28;323(16):1612-1614
pubmed: 32191259
J Appl Physiol (1985). 2005 Oct;99(4):1592-9
pubmed: 16160020
Sleep Breath. 2021 Jun;25(2):849-860
pubmed: 33907966
Clin Infect Dis. 2005 Oct 15;41(8):1089-96
pubmed: 16163626
Chest. 2009 Sep;136(3):772-778
pubmed: 19567497
J Hypertens. 1999 Sep;17(9):1297-300
pubmed: 10489107
Lung. 2007 May-Jun;185(3):173-8
pubmed: 17436039
Am J Respir Crit Care Med. 2002 May 1;165(9):1217-39
pubmed: 11991871
Sleep. 2003 Nov 1;26(7):851-6
pubmed: 14655919
Int J Mol Sci. 2019 Jan 22;20(3):
pubmed: 30678164
Sleep Vigil. 2021;5(2):267-274
pubmed: 34368616
Anesthesiology. 2008 May;108(5):812-21
pubmed: 18431116
BMJ Open Respir Res. 2021 Jan;8(1):
pubmed: 33436406
Sleep Vigil. 2021;5(1):111-118
pubmed: 33972929
Sleep Med Rev. 2021 Feb;55:101382
pubmed: 32980614
Int J Infect Dis. 2020 May;94:55-58
pubmed: 32251791
Proc Am Thorac Soc. 2008 Feb 15;5(2):136-43
pubmed: 18250205
J Clin Sleep Med. 2020 Sep 15;16(9):1645
pubmed: 32356516
Sleep Med Rev. 2017 Dec;36:57-70
pubmed: 27919588
Sleep Med. 2022 Mar;91:196-204
pubmed: 33678579
Sleep Med Rev. 2000 Dec;4(6):583-602
pubmed: 12531037
Indian J Crit Care Med. 2016 Jun;20(6):323-31
pubmed: 27390455
BMC Neurol. 2011 Mar 24;11:37
pubmed: 21435231
Ear Nose Throat J. 2021 Jul 28;:1455613211029783
pubmed: 34318690
Eur Respir Rev. 2015 Jun;24(136):327-39
pubmed: 26028644
Ann Intensive Care. 2022 Mar 9;12(1):23
pubmed: 35262794
Sleep. 1991 Dec;14(6):486-95
pubmed: 1798880